Novo Nordisk's CagriSema shows 25% weight loss in women, lifting obesity shares and ETFs
The next-generation combination readout is central to Novo's effort to defend its obesity franchise as price competition intensifies.
The Globe and Mail · +12 outlets
Pfizer halts development of closely watched weight-loss drug
The move removes one of the larger challengers to Novo Nordisk and Eli Lilly in the obesity market and follows persistent investor questions about Pfizer's meta
BusinessWorld Online · +9 outlets
Novo Nordisk halves US price of its weight-loss drug as price war escalates
Deep discounts on GLP-1 obesity drugs are reshaping the economics of the category for payers, patients and manufacturers.
BusinessWorld Online · +14 outlets
GSK wins FDA approval for hepatitis B drug bepirovirsen, offering patients a chance to stop long-term treatment
The approval gives hepatitis B patients a therapy that in trials allowed a minority to control infection without ongoing medication.
Reuters · +14 outlets
Eli Lilly to build $3.5B Pennsylvania weight-loss drug plant
The investment adds manufacturing capacity for Lilly's GLP-1 obesity drugs amid surging demand.
BusinessWorld Online · +14 outlets
Compounded GLP-1 injections recalled over lack of sterility assurance
The recalls follow FDA warnings and heighten scrutiny of unapproved compounded weight-loss alternatives.
Los Angeles Times · +14 outlets
Median drug launch prices hit $257,000 as access barriers persist, ICER and West Health report finds
The findings add to debate over whether US drug pricing policy changes have translated into lower costs for patients.
Pharmaceutical Executive · +13 outlets
India caps supply chain margins at 30% for 137 cancer drugs
The margin cap is intended to lower treatment bills for cancer patients in India.
BioWorld News · +14 outlets
Edwards Lifesciences wins FDA approval for PASCAL tricuspid repair system
The clearance expands transcatheter options for tricuspid valve disease.
Mugglehead Investment Magazine · +6 outlets
Japan's expanded drug price cuts draw industry backlash
Pharma groups are pushing back on annual price reductions that squeeze returns in the Japanese market.
BioWorld News
Alvotech shares jump after FDA approves new Simlandi manufacturing process
The approval supports the biosimilar maker's supply of its Humira copy.
Yahoo Finance Australia · +8 outlets
Roche's Ocrevus kept nine in 10 children with MS relapse-free for two years
The pediatric data supports broader use of the multiple sclerosis therapy in younger patients.
Stock Titan · +1 outlets
Pharma pushes for higher European drug prices, Trump or no Trump
European industry lobbying continues even as US policy pressure on drug pricing persists.
polskieradio.pl · +14 outlets
ImmunityBio locks Anktiva trial database, eyes November results as FDA filing nears
Upcoming data will inform the company's regulatory path for the bladder cancer therapy.
Yahoo Finance · +2 outlets
Cardiff Oncology's onvansertib gains FDA orphan drug status for rare blood cancer
Orphan designation can bring tax credits and other incentives for clinical development of the drug.
GuruFocus · +4 outlets
UroGen Pharma wins FDA filing acceptance for kidney-disease drug, PDUFA set for March 25, 2027
Filing acceptance starts the review clock for the company's candidate.
Stock Titan · +4 outlets
Pfizer weight-loss pipeline questions swirl as obesity dealmaking broadens beyond GLP-1s
Investors are looking at non-GLP-1 obesity assets as large pharma continues to shop for metabolic deals.
TradingView
Neurocrine Biosciences starts Phase 2 Alzheimer's trial
The study adds a new entrant to the crowded Alzheimer's pipeline.
Mugglehead Investment Magazine